Chewable Tablet Adverse Events, Manufacturing Slips Prompt Guidance
This article was originally published in The Gold Sheet
Executive Summary
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance document. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
You may also be interested in...
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”